Livia Alvarenga1, Ludmila F M F Cardozo2, Beatriz O Da Cruz2, Bruna R Paiva2, Denis Fouque3, Denise Mafra4,2,5. 1. Graduate Program in Medical Sciences, Fluminense Federal University (UFF), Niterói, Brazil. liviaalvarenga92@gmail.com. 2. Graduate Program in Cardiovascular Sciences, Fluminense Federal University (UFF), Niterói, Brazil. 3. Department of Nephrology, Centre Hopitalier Lyon Sud, INSERM 1060, CENS, Université de Lyon, Lyon, France. 4. Graduate Program in Medical Sciences, Fluminense Federal University (UFF), Niterói, Brazil. 5. Graduate Program in Biological Sciences-Physiology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Abstract
BACKGROUND AND OBJECTIVES: Recent studies have shed light on the potential role of curcumin in mitigating inflammation in patients with chronic kidney disease (CKD). This study aimed to evaluate the effects of curcumin supplementation on plasma levels of markers of inflammation and oxidative stress in patients with CKD undergoing hemodialysis (HD). METHODS: These are secondary exploratory analyses from a previous double-blind, randomized controlled pilot study registered under ClinicalTrials.gov Identifier no. NCT00123456. It included 28 hemodialysis patients from a previous study divided into two groups: curcumin group (receiving juice with 2.5 g of turmeric 3×/week for 12 weeks) and a control group. The TNF-α, IL-6 and Ox-LDL plasma levels were measured by sandwich enzyme immunoassays ELISA; lipid peroxidation was measured by the reaction between malondialdehyde (MDA) and thiobarbituric acid. RESULTS: After 12 weeks of supplementation with curcumin, the TNF-α plasma levels were significantly reduced [from 15.0 (8.23-73.3) to 6.17 (1.11-55.0) pg/mL, p = 0.01]. CONCLUSION: 12 weeks of treatment with curcumin in HD patients resulted in a reduction in the biomarker of inflammation (TNF-α), confirming our previous hypothesis that curcumin has an anti-inflammatory effect.
BACKGROUND AND OBJECTIVES: Recent studies have shed light on the potential role of curcumin in mitigating inflammation in patients with chronic kidney disease (CKD). This study aimed to evaluate the effects of curcumin supplementation on plasma levels of markers of inflammation and oxidative stress in patients with CKD undergoing hemodialysis (HD). METHODS: These are secondary exploratory analyses from a previous double-blind, randomized controlled pilot study registered under ClinicalTrials.gov Identifier no. NCT00123456. It included 28 hemodialysis patients from a previous study divided into two groups: curcumin group (receiving juice with 2.5 g of turmeric 3×/week for 12 weeks) and a control group. The TNF-α, IL-6 and Ox-LDL plasma levels were measured by sandwich enzyme immunoassays ELISA; lipid peroxidation was measured by the reaction between malondialdehyde (MDA) and thiobarbituric acid. RESULTS: After 12 weeks of supplementation with curcumin, the TNF-α plasma levels were significantly reduced [from 15.0 (8.23-73.3) to 6.17 (1.11-55.0) pg/mL, p = 0.01]. CONCLUSION: 12 weeks of treatment with curcumin in HD patients resulted in a reduction in the biomarker of inflammation (TNF-α), confirming our previous hypothesis that curcumin has an anti-inflammatory effect.
Authors: Liliana M Pedruzzi; Ludmila Ferreira Medeiros de França Cardozo; Renata F Medeiros; Milena B Stockler-Pinto; Denise Mafra Journal: J Bras Nefrol Date: 2015 Apr-Jun
Authors: Roberta T Salarolli; Livia Alvarenga; Ludmila F M F Cardozo; Karla T R Teixeira; Laís de S G Moreira; Jordana D Lima; Silvia D Rodrigues; Lia S Nakao; Denis Fouque; Denise Mafra Journal: Int Urol Nephrol Date: 2021-01-12 Impact factor: 2.370
Authors: Livia Alvarenga; Roberta Salarolli; Ludmila F M F Cardozo; Rhayssa S Santos; Jessyca S de Brito; Julie Ann Kemp; Drielly Reis; Bruna Regis de Paiva; Peter Stenvinkel; Bengt Lindholm; Denis Fouque; Denise Mafra Journal: Clin Nutr Date: 2020-03-13 Impact factor: 7.324